ArticleTranslational cancer research2025
Evaluating the efficacy of combined modality therapy versus chemotherapy alone in unresectable primary pulmonary diffuse large b-cell lymphoma: a retrospective cohort study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary pulmonary diffuse large B-cell lymphoma (PP-DLBCL) is a rare and aggressive extranodal lymphoma, with no consensus on optimal treatment strategies. For unresectable cases, current evidence is insufficient to determine whether the addition of radiotherapy (RT) to chemotherapy (CT) provides a survival benefit. To address this gap, we used data from the Surveillance, Epidemiology, and End Results (SEER) database to compare survival outcomes between combined modality therapy (CMT) and CT alone in patients with unresectable PP-DLBCL. Methods: Data on patients with unresectable PP-DLBCL were extracted from the SEER database of the National Cancer Institute, using SEER*Stat software (v8.4.3). Propensity score matching (PSM) was applied to adjusted confounding factors. Overall survival (OS) and cancer-specific survival (CSS) were estimated using Kaplan-Meier methods, and differences between groups were assessed using the log-rank test. Hazard ratios (HRs) were calculated using Cox proportional hazards models. Results: A total of 880 patients with unresectable PP-DLBCL diagnosed between 2000 and 2021 met the inclusion criteria and the median follow-up were 87 months. The estimated 5-year OS rate was 65.4% [95% confidence interval (CI): 60.1-70.7%]. Of these patients, 719 received CT alone and 161 received CMT. Significant differences in primary tumor site and laterality were observed between the two groups (P<0.001). The analysis revealed a significant association between CMT and improved OS (HR, 0.77; 95% CI: 0.59-0.99), and this association remained consistent in the sensitivity analysis using PSM. Additionally, univariate and multivariate Cox regressions indicated that sex, age and Ann Arbor stage were independent prognosis factors of OS. Conclusions: Our findings suggest that CMT may improve survival in patients with unresectable PP-DLBCL. Moreover, the prognostic factors identified in this study may help in identifying high-risk patients. Our findings provide new evidence to support the clinical management of this rare patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.